Fig. 2.

Association of early IFN therapy with reduced GC adverse effects on COVID-19 recovery. a, b Cumulative incidence curves for hospital discharge among survivors without (a) or with early IFN therapy (b). n = 84 (GC) and 87 (no GC) for a; 116 (GC) and 87 (no GC) for b. c, d Cumulative incidence curves for symptom relief among survivors without (c) or with early IFN therapy (d). n = 84 (GC) and 87 (no GC) for c; 116 (GC) and 87 (no GC) for d. e, f Bar graph of PVS prevalence among patients ceased viral shedding before discharge and without (e) or with early IFN therapy (f). n = 88 (GC) and 87 (no GC) for e; 116 (GC) and 87 (no GC) for f